Pharmacists in Smithville, MO Accepting Medicare
5 Pharmacists found. Showing 1 - 5
 Dr. Lyndon Gene Throm, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1103 S. 169 Hwy, Smithville, MO 64089 Phone: 816-532-0977 Fax: 816-532-8444 |
Dr. Madison Bennett, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1103 South 169 Highway, Smithville, MO 64089 Phone: 816-532-0977 Fax: 816-532-8444 |
 Dr. Stefanie Jean Throm, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15700 N Us Highway 169, Smithville, MO 64089 Phone: 816-532-6140 |
Christine Hashman, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 122 N Us Highway 169, Smithville, MO 64089 Phone: 816-532-6140 |
Alec David Schwartze, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1103 S Us Highway 169, Smithville, MO 64089 Phone: 816-532-0977 Fax: 816-532-8444 |
News Archive
Scientists discover network of flows that distribute messenger substances in the brain
We have all bumped our heads at some point, and such incidents are usually harmless. This is thanks to fluid-filled chambers in our brain that offset minor knocks and jolts and provide padding for sensitive components of our nervous system.
Health law mandates higher Medicare payment for osteoporosis tests
The Boston Globe: "A $3 million campaign by doctors, scanner operators, manufacturers, and groups devoted to women's health helped persuade lawmakers to overrule Medicare administrators this year and restore much of the reimbursement for osteoporosis tests. In a little-noticed provision buried deep in the sweeping new health care bill, Congress decreed that Medicare shall pay $97 for each test, instead of $50.
CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000
CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009. For the quarter CPEX reported revenues of $5.0 million and a net loss of $872,000.
With end-of-enrollment surge behind them, insurers see health law positives
Politico reports that many insurers are contemplating expanding - or initiating - their participation in exchanges. Other news outlets examine tax day, the health law and the Internal Revenue Service.
No progression in joint damage in 84% of psoriatic arthritis patients
Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.
› Verified 7 days ago
Dentists
Pharmacists
Counselors
Psychologists
Clinical Social Workers
Occupational Therapists